Visiting Dana-Farber? See our prescreening and mask requirements.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Read about advances in hematologic malignancies in our biannual eNewsletter for clinicians nationwide in the field of hematologic oncology.
Welcome to the inaugural issue of Advances in Hematologic Malignancies, the new Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) eNewsletter for providers across the country and around the world who hold an interest in the field.
One of the most rapidly progressing fields in medical oncology is that of hematologic malignancies.
A 41-year-old man presented with 4 weeks of progressive dysphagia, reflux, involuntary weight loss, night sweats, dyspnea on exertion, and an enlarging left neck mass.
The Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) Adult Lymphoma Program operates a large and growing research program.
Our translational research group focuses on the pathogenesis and treatment of aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). DLBCL, the most common non-Hodgkin lymphoma in adults, is a clinically and genetically heterogeneous disorder.
Improvements in the diagnosis of lymphoma and therapeutic strategies have led to important gains in survival over the past several decades.
If you are a clinician specializing in the field of hematologic oncology, we can help you refer a patient, explore open clinical trials, learn about CME events, and more.
View our full list of hematologic malignancies resources for referring providers.